Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold
gene-modified vaccine cells combined with a TLR-9 agonist by Volz, Barbara et al.
Citation: Molecular Therapy — Oncolytics (2016) 3, 15023; doi:10.1038/mto.2015.23 
Official journal of the American Society of Gene & Cell Therapy All rights reserved 2372-7705/16
www.nature.com/mto
INTRODUCTION
Tumor vaccines restore the immune system’s intrinsic ability to 
recognize tumor cells. Cell-based tumor vaccines are classified as 
dendritic cell (DC)-, T-cell- or tumor cell-based vaccines. For the lat-
ter one, tumor-specific effects were shown including activation of 
T cells and strengthening of CD8+T-cell responses by direct antigen 
activation and cross-priming, development of memory cells, and 
increase of antibody-based response.1,2 Cell-based tumor vaccines 
own a huge reservoir of tumor-related antigens and are, there-
fore, able to address a broad repertoire of T cells. Plurality of anti-
gens on cell-based vaccines hampers immune escape of the tumor 
cells by selective antigen loss. However, individual antigens of the 
 cell-based vaccines evoke a rather weak immune response under-
lining the necessity to strengthen their immunogenicity by multiple 
gene modifications.
Preparation of multiple gene-modified cells requires  high-efficient 
expression vectors. Recently, MIDGE (minimalistic immunogenically 
defined gene expression) DNA vectors were developed for clinical 
use3–5 allowing the generation of multiple gene-modified cells with 
only minimal amount of foreign DNA. MIDGE vectors display a lin-
ear covalently closed topology with single-stranded loops and are 
biotechnologically manufactured from plasmids. Their small size of 
about 1,200 bp plus coding sequence is based on their exclusive 
content of the expression cassette consisting of the CMV promoter, 
the selected coding sequence, and a poly(A) signal. The preven-
tion of genes for resistance to antibiotics, of replication origins, and 
other functional elements improves their overall safety profile and 
ensures that application of MIDGE vectors does not add conflicting 
potential to public health issues.
Transient gene modification of cells helps to maintain their 
 natural expression profiles by minimizing adaptation processes 
following otherwise stable transfection. Additionally, waiving 
clonal selection preserves the heterogeneity of cells representing 
all  subtypes outgrown from original tumor tissue. Preservation of 
the antigen  repertoire of the source cell line during the manufactur-
ing process to vaccine cells is important because this repertoire is a 
main criterion for selection of source cells.
Besides the selection of cell line, vector, and gene modification, the 
identification of an additional immunomodulator as multiplier of the 
tumor-specific immune response is crucial. Toll-like receptor 9 (TLR-9) 
agonists are powerful connectors of innate and adaptive immunity 
and therefore supposed to be ideally suited to strengthen tumor vac-
cines.6 dSLIM (double stem loop immunomodulator) is a noncoding 
dumbbell-shaped and covalently closed DNA molecule with non-
methylated CG motifs acting via TLR-9 (refs. 7–9). Currently, dSLIM is 
evaluated in clinical trials for the treatment of solid tumors.10,11
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The tumor vaccine MGN1601 was designed and developed for treatment of metastatic renal cell carcinoma (mRCC). MGN1601 
consists of a combination of fourfold gene-modified cells with the toll-like receptor 9 agonist dSLIM, a powerful connector of 
innate and adaptive immunity. Vaccine cells originate from a renal cell carcinoma cell line (grown from renal cell carcinoma tissue), 
express a variety of known tumor-associated antigens (TAA), and are gene modified to transiently express two co-stimulatory 
molecules, CD80 and CD154, and two cytokines, GM-CSF and IL-7, aimed to support immune response. Proof of concept of the 
designed vaccine was shown in mice: The murine homologue of the vaccine efficiently (100%) prevented tumor growth when used 
as prophylactic vaccine in a syngeneic setting. Use of the vaccine in a therapeutic setting showed complete response in 92% of 
mice as well as synergistic action and necessity of the components. In addition, specific cellular and humoral immune responses 
in mice were found when used in an allogeneic setting. Immune response to the vaccine was also shown in mRCC patients treated 
with MGN1601: Peptide array analysis revealed humoral CD4-based immune response to TAA expressed on vaccine cells, including 
survivin, cyclin D1, and stromelysin.
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Renal cell carcinoma (RCC) is well known for its response to 
immune therapies.12,13 Launch of targeted therapies has improved 
treatment of patients with metastatic RCC. However, RCC, especially 
at metastatic stage, remains a life-threatening condition with high 
medical need for effective treatment.
The aim of the current work was to develop a tumor vaccine for 
an improved treatment of metastatic renal cell carcinoma (mRCC). 
During our previous development of tumor vaccines, cells derived 
from autologous tumor tissue were gene modified to discretely 
express IL-2, IL-7, IL-12, or granulocyte-macrophage colony-stimulat-
ing factor (GM-CSF).14–16 The use of twofold  gene-modified vaccine 
cells secreting IL-7 and GM-CSF presented a new milestone in autolo-
gous vaccine development.17 In this study, 50% of treated patients 
showed clinical response to treatment with at least disease stabi-
lization. Encouraged by these results and driven by the increased 
knowledge and immunological understanding of tumor vaccines,18 
additional gene modification of vaccine cells (besides cytokines) 
with co-stimulatory molecules CD80 (ref. 19) and CD154 (refs. 20,21) 
was chosen. These modifications were supposed to further improve 
immune response to the vaccine antigens by mimicking features 
of antigen presenting cells (APC) and T cells and result in fourfold 
 gene-modified cells.
The concept of fourfold gene-modified cells was evaluated in mice, 
using a murine vaccine consisting of murine tumor cells and express-
ing murine cytokines and co-stimulatory molecules in combination 
with the TLR-9 agonist dSLIM. Proof of concept of the antitumor effi-
cacy was shown as well as cellular and humoral immune responses. 
Multiple toxicological studies did not reveal any safety concerns. 
The next developmental step was the identification a human cell 
line for generation of a human vaccine. B25MOL cells were selected 
as source material for the vaccine due to their success in an autolo-
gous treatment schedule of an mRCC patient (complete response for 
7 years, survival for 13 years) and their broad expression of tumor-
associated antigens (TAA). Fourfold (CD80, CD154, GM-CSF, and IL-7) 
gene-modified vaccine cells were combined with the TLR-9 agonist 
dSLIM—resulting in MGN1601. Expression characteristics of vaccine 
cells were analyzed. The immune responses shown in murine studies 
were confirmed in translational analyses with blood samples from 
patients treated within the ASET (Assess Safety and efficacy of the 
Tumor Vaccine MGN1601) study with MGN1601.
ReSUlTS
Efficacy of the designed vaccine in murine tumor models (syngeneic 
setting)
In order to evaluate the efficacy of the designed vaccine for treat-
ment of RCC, a murine homologue of the vaccine was manufac-
tured. This vaccine consisted of fourfold gene-modified murine RCC 
cells (Renca), combined with dSLIM.
Use as prophylactic vaccine. First, the immunotherapeutic concept 
was assessed by prophylactic vaccination in a syngeneic mouse 
model. Balb/c mice were treated four times with the murine 
homologue before tumor growth was initiated by inoculation of 
Renca cells (Figure 1a,b). All mice of the vaccinated group survived, 
and none of them developed a tumor at any time of the experiment 
(Figure  1a). In contrast, 70% of mice treated with  phosphate-
buffered saline (PBS) developed a tumor, and none of the  tumor-
bearing mice survived the experimental period due to tumor 
growth. In vaccinated mice, tumor-free survival as well as total 
survival were significantly increased (P  <  0.001; Figure  1b). These 
data unequivocally proved that prophylactic vaccination with the 
newly designed vaccine protects mice from tumor development 
after inoculation of Renca cells.
Use as therapeutic vaccine. The newly designed concept was further 
evaluated by therapeutic vaccination using different variants 
of the vaccine (murine homologue). Balb/c mice first received 
Renca cells for tumor inoculation. One week later, treatment was 
started (Figure  1c,d and Supplementary Table S1). Treatment was 
repeated three times (n = 12 mice/group). One important goal of 
the study was to evaluate the efficacy of experimental variants of 
the vaccine to inhibit tumor growth and thus the necessity of the 
components within the therapeutic concept. Complete vaccine 
(“complete”) was compared to the efficacy of vaccine cells without 
the immunomodulator dSLIM (“tf Renca”  fourfold gene-modified 
Renca cells), to irradiated Renca cells (“Renca”  without gene 
modification, without dSLIM), and to dSLIM as single component 
(“dSLIM”).
Mean tumor volume at the end of the study or at the date of 
death of a mouse was 1,370 mm3 for mice receiving PBS (Figure 1c), 
whereas mice treated with the murine homologue showed an aver-
age tumor volume of 69 mm3 (11 mice without tumor and 1 mouse 
with 832 mm3 tumor volume). Experimental variants of the vaccine 
used resulted in mean tumor volumes between those of PBS- and 
vaccine-treated mice. Tumor volumes of mice treated with “com-
plete vaccine” or with “tf Renca” were statistically significant lower 
(P  <  0.001) compared to those of PBS-treated mice. Furthermore, 
tumor volumes of mice treated with “dSLIM” as monotherapy were 
significant lower (P < 0.05), whereas tumor volumes of mice treated 
with “Renca” showed no significant reduction. These data are sum-
marized in Supplementary Table S1.
Tumor growth in tumor-bearing mice of all five treatment groups 
was compared over the time course of the study (Figure  1d and 
Supplementary Figure S1). All vaccinated animals showed reduced 
tumor growth compared to PBS-treated mice. However, the com-
plete vaccine achieved the most prominent effects. Furthermore, 
the survival rate of tumor-bearing mice was highest (92%) for mice 
treated with the complete vaccine, whereas all tumor-bearing mice 
treated with PBS died during the study due to tumor-related rea-
sons. Survival data of mice in the other three treatment groups 
ranked between those of PBS and complete vaccine groups: 
“tf Renca”: 75%, “Renca”: 50%, and “dSLIM”: 17%.
Mice that had been classified as tumor bearers during the study 
but finished the study without measurable tumor size were classified 
as “complete remission.” Eleven out of 12 tumor-bearing mice of the 
complete vaccine group were free of tumor at the end of the study, 
resulting in 92% complete remission rate. In contrast, none of the 
PBS-treated mice showed any reduction of tumor volume at any time 
point. The variants of the vaccine showed intermediate complete 
remission rates: “tf Renca”: 66%, “Renca”: 50%, and “dSLIM”: 17%.
In summary, the newly designed therapeutic concept was identi-
fied as superior over other tested experimental variants underlining 
the relevance and potential synergistic effects of the vaccine cells, 
their gene modification, and the TLR-9 agonist dSLIM.
Immunomodulating effects of the vaccine in mice (allogeneic 
setting)
Next, the immunomodulatory effects of the vaccine were addressed. 
Again, the murine homologue of the vaccine was repeatedly applied 
(8 to 13 times) once weekly to NMRI mice (Naval Medical Research 
Institute mouse strain, allogeneic to Renca cells).
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Attraction of APC and T cells to the application site. Skin sections of 
the injection sites of the vaccine were analyzed for the presence 
of T cells (CD4+ or CD8+ cells) and APC (CD86+ cells) in NMRI mice. 
A bright staining intensity for CD4+ and CD8+ T cells, as well as for 
APC (CD86+ cells) was seen in mice treated repeatedly (eight times) 
with the vaccine, while skin sections of application sites of  PBS-
treated mice did not stain for any of the analyzed cell populations 
(Figure  2a and Supplementary Figure S2). These findings indicate 
the recruitment of T cells and APC by the vaccine to the injection 
sites.
Induction of vaccine specific antibodies. Sera of vaccinated mice were 
analyzed for Renca-specific antibodies after eight applications of the 
vaccine (Figure 2b). Sera of all vaccinated mice clearly recognized 
Renca cell lysates (titer 11,000 to 35,000), while sera of PBS-treated 
mice did not react at all, indicating high  CD4+-dependent B-cell 
responses to the vaccine.
Induction of vaccine-specific cytotoxicity. Mice were vaccinated 
repeatedly (13 times) with either low dose or high dose of the 
vaccine (murine homologue) in an allogeneic setting. Thereafter, 
spleen cells were isolated, re-stimulated with Renca cells ex vivo, 
and analyzed for specific cytotoxicity against Renca cells as target 
(Figure  2c). Highest Renca-specific cytotoxicity of spleen cells 
was found in the high-dose group, although all examined groups 
showed pronounced lytic activities for Renca cells if compared 
to spleen cells from PBS-treated mice. Cytotoxicity of spleen cells 
was maintained even 4 weeks after the last high-dose application 
(recovery group), indicating a sustained CD8+-based immune 
response against the vaccine cells.
Evaluation of safety
To assess the safety of the tumor vaccine, single- and  repeated-dose 
toxicological studies were performed using either MGN1601 in rats 
(heterologous model) or the murine homologue in mice (homolo-
gous model, allogeneic setting) according to regulatory require-
ments. In the heterologous setting, the single administration of 
up to a 500-fold excess regarding the human dose (per kg body 
weight) as well as the repeated application (five times) of up to a 
60-fold excess did not result in any relevant toxicological findings. 
In the homologous model, the murine vaccine was applied to NMRI 
mice. Repeated application (13 times) of up to a 3,000-fold excess 
regarding the human dose resulted in only minor observations 
Figure 1 Vaccination studies using the murine vaccine in Balb/c mice (syngeneic setting). (a and b) Prophylactic vaccination study. Mice received 
four weekly injections of the murine homologue of the vaccine (n = 10) or PBS (n = 10). Thereafter, tumor inoculation with Renca cells was performed. 
(a) Tumor volume of tumor-bearing mice, given as mean + SD and (b) survival of all mice was assessed for 60 days after tumor inoculation. A 
representative study is shown. (c and d) Therapeutic vaccination study using a range of experimental variants of the vaccine. Mice received tumor 
inoculation with Renca cells and, subsequently, 4 weekly injections with vaccine variants (n = 12 mice/group). (c) Mean (+) and median tumor volume, 
5–95% confidence intervals, + SD for each treatment group are shown. For calculation of mean tumor size, the tumor volume of surviving mice at day 
60 as well as the tumor size of nonsurvivors measured before death was used. Statistical analysis was done by one-way analysis of variance followed 
by Tukey’s test ***P < 0.001, *P < 0.05, n.s., not significant; P > 0.05 (versus PBS-group). (d) Tumor growth. Average tumor size per time was calculated 
from all  tumor-bearing mice (6–12 mice) of the respective treatment group. Arrows indicate vaccinations.
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representing most probably immune activation due to the antici-
pated pharmacodynamic effects of the vaccine. Observations 
included a reversible increase of 35% (statistically significant with 
P  <  0.01, only for female mice) in absolute and relative spleen 
weight (Supplementary Figure S5) as well as lymphoid hyperplasia 
of the lymph nodes. Additionally, histopathology of the injection 
sites revealed infiltration by mononuclear cells and granuloma-
tous inflammation. No signs for systemic toxicity of MGN1601 or its 
murine homologue were observed.
Selection and characterization of B25MOL cells as basis for 
MGN1601
After proof of concept of the designed vaccine was shown in mice, 
the next aim was the transition of the murine to a human vaccine for 
mRCC patients. This translational effort required the identification of 
a suitable cell line. In order to assure a comprehensive presentation 
of TAA by the vaccine cells, the cell line used as source for vaccine 
preparation was carefully selected. Selection was done on the basis 
of 17 cell lines each established from tumor material of patients with 
RCC obtained during nephrectomy. These cell lines had been used 
for the preparation of autologous vaccines. Based on propagation 
characteristic and clinical response, cell line B25MOL was chosen 
for further development of an allogeneic tumor vaccine. B25MOL 
cells originate from tumor material of a female patient with clear cell 
mRCC (stage IV with multiple metastases (pT3a pTx G3)). Tumor tis-
sue showed outgrowth of cells after 6 weeks of cultivation, and cells 
exhibited stable propagation. No clonal selection was performed. 
After four autologous vaccinations with gene-modified B25MOL 
cells expressing IL-7 and GM-CSF over a course of 6 weeks, the 
patient showed complete clinical response (lasting for 7 years and 
resulting in 13 years of survival) with disappearance of all metasta-
ses indicating immunologically favored characteristics of these cells. 
A master cell bank of B25MOL cells was manufactured, stored, and 
certified for use in humans. Stability of transcriptome was analyzed 
by comparison of RNA of B25MOL cells after initial and late round of 
seeding of a master cell bank aliquot (Figure 3a). From 32,000 genes 
analyzed, only 5 changed expression more than threefold between 
passage 20 and passage 40. Three of these genes were not anno-
tated at the time of analysis and two coded for small nucleolar RNA 
(SNORA36C and SNORA36A) involved in the modification of 18S 
rRNA. mRNA data of the cells used as source for the vaccine showed 
expression of TAA (see Supplementary Table S2). Congruency of 
mRNA data and protein expression data was evaluated for 242 sur-
face proteins, easily accessible for fluorescence-activated cell sort-
ing. Besides a few exceptions, correlation was roughly given. Out of 
the analyzed antigens, 102 were clearly expressed (geometric mean 
value higher than threefold of respective isotype control). From 
those, about a dozen are described as immunogenic or are even in 
use as components of tumor vaccines, including CD40, CD44, CD54 
(ICAM), CD73, CD95 (FAS), CD105 (TGF-β receptor complex, endog-
lin), CD146 (MCAM), CD151, CD227 (MUC1), CD326 (EpCAM), CD340 
(Her-2/neu), EGFR, and Met (Figure 3b).
Gene modification of B25MOL cells
Four different MIDGE vectors each coding for the expression of 
CD80, CD154, GM-CSF, or IL-7 were used for transient gene modi-
fication of B25MOL cells. Thereafter, gene-modified B25MOL cells 
were gamma-irradiated to prevent further propagation of cells.
Typically, about 50% of vaccine cells expressed CD80 as well as 
CD154 (Figure  4a) on their cell surface. Concomitantly, vaccine 
cells secreted the cytokines GM-CSF and IL-7. Both accumulated 
in the culture supernatants and were quantified to 38,035 ± 9,266 
(GM-CSF) and 3,815 ± 703 (IL-7) pg/1 × 106 cells/4 hours. Secretion 
data of cytokines are given as mean (± SD) of eight batches (N = 8), 
representing >2 × 1010 vaccine cells. Concentration of GM-CSF was 
Figure 2 Immune response to treatment of NMRI mice with the murine 
vaccine (allogeneic setting). (a) Staining intensity of skin sections at the 
application site of the murine vaccine after 8 weekly injections. Skin 
sections of the application sites were analyzed by immunohistochemistry 
for the presence of CD4+-, CD8+-, and CD86+- cells. Staining intensity 
was recorded as 0 for “no staining,” as 1 for “slight staining,” as 2 for 
“moderate staining,” and as 3 for “pronounced staining.” Two injection 
sites per animal were analyzed, resulting in 20 analyses per parameter. 
Analytical results and mean  +  SD are shown. Statistical analysis was 
done by Student’s t-test; ***P < 0.001. (b) Titer of antibodies reactive 
to Renca cells after 8 weekly vaccinations. One week thereafter, serum 
was gained and analyzed by enzyme-linked immunosorbent assay for 
antibodies reactive to Renca lysate. Dilution of serum is given as titer. 
Analytical results as well as mean + SD are shown. Statistical analysis was 
done by Student’s t-test; ***P < 0.001. (c) Cytotoxicity of spleen cells of 
mice repeatedly vaccinated with low dose (12 mice) or high dose of the 
murine vaccine (22 mice) or PBS (12 mice). One week (recovery group: 5 
weeks) after the 13th application, spleen cells were isolated and analyzed 
for cytotoxicity toward Renca cells. The respective value of PBS-treated 
mice was subtracted. Statistical analysis was done by one-way analysis 
of variance followed by Tukey’s test. *P < 0.05 (versus high dose of the 
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about 10 times higher than that of IL-7, indicating different secre-
tory potentials for the two cytokines by the vaccine cells.
A 6-day culture of vaccine cells confirmed the higher secretory 
capacity of GM-CSF (Figure  4b). The concentration of IL-7 in the 
supernatant increased for about 1 day and was stable thereafter, 
while the concentration of GM-CSF increased pronounced within 
the first 24 hours and moderate thereafter. Furthermore, the expres-
sion of CD80 on the surface of living cells remained almost constant 
over several days. Due to the irradiation of gene-modified B25MOL 
cells, the percentage of living cells constantly dropped after a 
lag phase of about 10 hours until day 14 when no viable cell was 
detected.
Expression of cytokines was additionally analyzed in vivo. For 
this, a murine homologue of the vaccine (murine Renca cells, 
 gene-modified with murine forms of CD80, CD154, GM-CSF, and 
IL-7, in combination with dSLIM) was manufactured. In vitro expres-
sion data were comparable to MGN1601 (Figure 4c, data of cytokine 
secretion: 25,295 pg/4 hours × 1 × 106 cells (± 10,852) for GM-CSF 
Figure 3 mRNA and protein expression data of B25MOL cells. (a) Stability of mRNA expression during cultivation of B25MOL cells via microarray. Passage 
20 and 40: two biological replicates per analyzed passage, 10 microarrays in total are compared. The expression ratio (log base 2) of each spot is plotted 
against its average expression intensity of the probe sets. Dark diamonds identify the two differentially expressed annotated genes (SNORA36C and 
SNORA36A). Analysis of mRNA data was performed by Robust Multiarray Average preprocessing and Linear Model for Microarray data. Differential 
expressed genes are defined to show at least threefold changes of expression and a P value of moderate t-statistic of 0.05 at maximum. See also 
Supplementary Table S1. (b) Expression of selected cell surface antigens on B25MOL cells via flow cytometry. Histograms of antibody stained B25MOL 
cells (bold black lines) and corresponding isotype controls (gray lines) are shown. A representative histogram for each antigen is shown. At least 5 (up 
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and 660 pg/4 hours × 1 × 106 cells (± 143) for IL-7 (N = 7), represent-
ing about 5 × 109 vaccine cells). The murine homologue was injected 
s.c. to mice in an allogeneic setting. The concentration of the murine 
cytokines GM-CSF and IL-7 at the injection sites was analyzed in 
biopsy homogenates at various time points after application of the 
vaccine (Figure 4d). Cytokine concentration increased after applica-
tion for up to 8 hours and decreased thereafter. Fluctuation in indi-
vidual cytokine concentration is most probably due to the fact that 
biopsies do not perfectly co-localize with the site of highest cyto-
kine concentration. The concentration of GM-CSF in vivo was clearly 
higher (10–20 times) than that of IL-7, confirming the in vitro secre-
tion characteristics.
Comparison of expression characteristic of B25MOL cells and 
vaccine cells
B25MOL cells own a unique repertoire of potentially immunogenic 
TAA. Maintenance of this profile during their manufacturing process 
to vaccine cells is an important goal. Comparison of expression of 
cell surface proteins from B25MOL cells and engineered vaccine 
cells is shown in Figure 5. Geometric mean values of antigens on 
B25MOL cells and on vaccine cells are mainly similar, indicating con-
stant expression of the analyzed surface proteins. Especially highly 
expressed proteins (geometric mean values > 100) show only mar-
ginal changes in their surface expression. Besides the expected 
increase in expression of CD80 and CD154 two ABC transporters 
show higher expression (7.4-fold for CD338 and 2.7-fold for CD243) 
as well as CD15, SSEA-1, and disialoganglioside. Reduced expres-
sion was only noted for CD201 and MUC1 (CD227). Both molecules 
got lost from the cell surface during manufacturing of B25MOL cells 
to vaccine cells, probably due to either a shedding process because 
their soluble forms are described22,23 or an increase in intracellular 
compartments. Comparison of expression of selected surface-TAA 
in B25MOL cells and vaccine cells is shown in Figure 5b. Expression 
of TAA is highly preserved on vaccine cells indicating the mainte-
nance of the characteristics of B25MOL cells in engineered vaccine 
cells. Furthermore, expression data of mRNA analyzed by microar-
rays remain mainly on similar levels in the vaccine cells compared to 
B25MOL cells (K. Heinrich, personal communication).
Figure 4 Expression analysis of vaccine cells. (a) Expression of CD80 and CD154 in vaccine cells of MGN1601: vaccine cells were cultivated for 4 hours, 
thereafter stained with CD80-FITC and CD154-APC (right) or the respective isotype controls (left) and analyzed by flow cytometry. Co-expression 
of CD80 and CD154 is shown in a representative dot plot of vital cells. The percentage of positive and vital cells within all cells (vital plus nonvital) 
is depicted within the respective gates. (b) Kinetic of expression in vitro: vaccine cells were cultivated for the indicated periods, up to 125 hours. 
Accumulation of cytokines (GM-CSF in blue, IL-7 in green) in the culture supernatant was analyzed by enzyme-linked immunosorbent assay. 
Concentration of cytokines IL-7 (pg/100,000 cells) and GM-CSF (pg/5,000 cells) is depicted on the right y-axis. Expression of CD80 (percentage within 
living cells, red) and the ratio of living cells (black) was analyzed by flow cytometry and is indicated on the left y-axis: gated cells (%). Due to irradiation 
of cells the percentage of viable cells decreases within days. (c) Expression of CD80 and CD154 in vaccine cells of the murine homologue of MGN1601: 
vaccine cells were cultivated for 4 hours, thereafter stained with CD80-FITC and CD154-PE (right) or the respective isotype controls (left) and analyzed 
by flow cytometry. Co-expression of CD80 and CD154 is shown in a representative dot plot of vital cells. The percentage of positive and vital cells within 
all cells (vital plus nonvital) is depicted within the respective gates. (d) Kinetic of expression of cytokines in vivo. Murine homologue of MGN1601 was 
applied to mice and the presence of GM-CSF and IL-7 in biopsy-homogenates of the injection sites was analyzed by enzyme-linked immunosorbent 
assay. Relative concentration is displayed as mean + SD of six biopsies (three animals per point in time, each left and right side). 100% was assigned to 
the mean value at 8 hours after application. The inset shows the absolute concentration of GM-CSF (left y-axis) and Il-7 (right y-axis). For the preparation 
of homogenates, the tissue samples were diluted for about factor 5 with PBS. Therefore, the concentration of the cytokines in vivo is about 5 times 
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Induction of TAA-specific antibodies by MGN1601 in patients
After assuring that the human vaccine expresses the analyzed TAA, 
co-stimulatory molecules, and cytokines, the translational course 
was continued, and a phase 1/2 clinical trial (ASET) was performed 
to assess safety, efficacy, and immunological effects of MGN1601 
in mRCC cancer patients24 (V. Grünwald, S. Weikert, I.G.H. Schmidt-
Wolf, S. Hauser, A. Magheli, K. Kapp et al., personal communication). 
Here, the translational analyses regarding CD4-based humoral 
immune responses are in the focus in order to strengthen the devel-
opmental process from mice to men.
In short, 19 heavily pretreated patients with mRCC were included 
to receive eight doses of MGN1601 within 12 weeks (intended-to-
treat)—with 10 of them completing the treatment per protocol (PP). 
Application of MGN1601 to patients was safe and well tolerated. 
Notably, the PP-treated patients showed significantly increased 
overall survival (P < 0.05, median overall survival at final study analy-
sis of 115.3 weeks) over the intended-to-treat population.24 Here, the 
humoral immune response of MGN1601-treated patients against 
TAA expressed on vaccine cells was evaluated. For this purpose, sera 
of the PP-treated patients from the ASET study were analyzed for 
their binding properties to 17 known TAA—each represented on an 
array by overlapping peptides (Table 1). The serum of each patient 
showed binding to peptides either not recognized by their respec-
tive pre-immune serum or with a clearly increased intensity after 
MGN1601 treatment (shown for a single patient in Supplementary 
Figure S3). In average, serum of each patient recognized 37 out of 
4,399 peptides (±29, N = 10).
Each analyzed antigen was recognized by sera of two to eight 
patients (Table 1). Within each analyzed antigen, only a subset of 
overlapping peptides was recognized, whereas most peptides were 
not recognized indicating that these subsets own preferred immu-
nogenic characteristics to induce an immune response (Figure 6 and 
Supplementary Figure S4). Remarkably, some of these overlapping 
peptides were recognized by sera of more than one patient (“shared 
immune response”): in particular, 50–70% of treated patients shared 
response to immunogenic regions within survivin, stromelysin, 
c-myc, Histone H1.2, and G1/S-specific cyclin-D1, indicating their 
comprehensive immunogenic potential (Table  1). Furthermore, 
20–40% of treated patients shared immune response to peptides 
within G2/mitotic-specific cyclin-B1, Met, PRAME, telomerase, p53, 
apolipoprotein L1, and MAGE A1, whereas the antigens MUC1, 
NY-ESO-1, WT-1, Her-2/neu, and MAGE A3 did not show any over-
lapping peptides recognized by more than one patient. However, 
individual immune responses against peptides within these anti-
gens could be detected confirming their immunogenic potential, 
i.e., 7 out of 10 patients developed antibodies against Her-2/neu, 
and 3 patients against NY-ESO-1 and MAGE A3.
DISCUSSION
A variety of cancer vaccines are currently evaluated in clinical trials, 
and sipuleucel-T (DC-based) is the first tumor vaccine25 approved 
by the US Food and Drug Administration (2010) and European 
Medicines Agency (2013). Here, the development of a new kind of 
cell-based tumor vaccine, MGN1601 consisting of fourfold gene-
modified vaccine cells (originally derived from tumor material) in 
combination with the TLR-9 agonist dSLIM, is described as well as 
its translation from use in mice to its application in patients.
For the proof-of-concept studies, a syngeneic vaccination model 
was chosen. Use of the murine homologue of MGN1601 in a syn-
geneic murine setting unambiguously showed repression of tumor 
growth: tumor growth was completely repressed if the vaccine 
was applied in a prophylactic setting adding up in a survival rate of 
100% (Figure  1b). Thereafter, in the therapeutic setting, efficacy of 
experimental variants of the vaccine was compared to evaluate the 
therapeutic concept. Therapeutic application of the murine vaccine 
impressively reduced tumor growth in mice (Figure 1d). It was demon-
strated that the combination of the vaccine cells, their fourfold gene 
modification, and the TLR-9 agonist dSLIM are necessary to achieve 
effective antitumor properties probably by synergistic effects, e.g., by 
linking of innate and adaptive immunity.6,26,27 For syngeneic models, 
it is known that gene modification of vaccine cells improves survival 
of mice in melanoma models (B16F10 and K1735-M2).28 Due to the 
complete match of MHC molecules of vaccine cells with the tumor 
cells, the immunological stimulus is weaker compared to allogeneic 
setting, but it is intrinsically assured that the TAA expressed by the 
growing tumor are also expressed by the vaccine cells. The shared 
expression of TAA by vaccine cells and tumor cells is supposed to 
be crucial for the induction of a protective immune response. This 
Figure 5 Comparison of surface antigen expression of B25MOL cells and vaccine cells. (a) Expression ratio of 242 human cell surface markers was 
compared by BD Lyoplate. Antigens with expression level exceeding three times the respective isotype control were identified and compared for 
both kinds of cells (120 antigens). (b) Expression ratio of 13 selected TAA was compared by flow cytometry. For individual antigens, this analysis was 
independently repeated three to six times. Quotient of geometric mean values (vaccine cells/B25MOL cells) is displayed on the y-axis, whereas on the 
x-axis, the mean geometric mean value of both kinds of cells for each antigen (after correction for the respective isotype controls) is shown.
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aspect is not assured by an allogeneic murine vaccination setting and 
requires the careful selection of a suitable cell line. Therefore, in the 
human situation, the expression of TAA in B25MOL cells was a critical 
aspect for their selection as basis of the vaccine.
MGN1601 was designed to mainly induce an especially Th1-
based immune response against tumor cells. IL-7, a potent growth 
factor for T-cells, should support activation, maturation, and prolif-
eration of T cells involved in MGN1601 response, whereas presence 
Table 1 Analysis of patients’ sera by peptide array: identification of shared immune responsesa
















Survivin BIRC5 9.0 71 7 7 36–40 1, 4, 8, 9, 16, 17, 19
Stromelysin 3 MMP11 8.0 244 7 6 98–100 1, 4, 8, 9, 10, 16
3 155–156 1, 8, 17
3 178–183 8, 9, 17
3 223–225 4, 8, 9
c-myc MYC 10.2 219 7 5 12–19 4, 8, 9, 10, 16
5 130–135 1, 8, 9, 16, 17
Histon H1.2 HIST1H1C 9.4 106 6 4 12–18 1, 9, 10, 14
5 69–108 1, 9, 10, 16, 19
G1/S-specific cyclin-D1 CCND1 11.1 148 5 2 38–40 8, 17
5 138–144 8, 9, 10, 16, 17
G2/mitotic-specific cyclin-B1 CCNB1 9.6 217 8 4 51–57 1, 16, 17, 19
Met MET 12.6 692 8 2 81–84 4,17
2 147–151 10, 19
2 554 3, 10
3 611 8, 17, 19
2 650 4, 10
PRAME PRAME 7.8 262 5 2 27–29 4, 9
3 102–104 4, 10, 14
Telomerase TERT 8.1 566 8 3 221–223 4, 8, 17
2 435–437 9, 10
p53 TP53 9.6 197 5 2 42–47 8, 16
2 180–181 1, 3
Apolipoprotein L1 APOL1 10.2 199 3 2 161–163 9, 10
MAGE A1 MAGEA1 6.6 155 3 2 132–133 9, 17
Her-2/neu ERBB2 8.7 627 7 0 — —
Mucin 1 MUC1 8.1 236 5 0 — —
NY-ESO-1 CTAG1A 8.0 91 3 0 — —
MAGE A3 MAGEA3 6.8 164 3 0 — —
WT-1 WT1 7.8 224 2 0 — —
PP, per protocol.
aSera of all PP-treated patients (N = 10) from the ASET study were collected before the first vaccination and after eight vaccinations (week 12) and analyzed for binding 
intensity to 17 antigens. Each antigen was represented by successive 15-mer peptides with an overlap of 13 amino acids. Each peptide was spotted in duplicate to 
the array. Immune response to peptides was identified when three criteria were fulfilled: high binding intensity (>1,000) of the serum combined with a greater than 
twofold increase of binding signal compared to the preimmune sera and binding intensity to overlapping peptides (with at least binding signal of 500). Number of 
patients with individual immune response to peptides of the respective antigen is given. Additionally, the number of patients with shared immune responses is given 
(more than one serum binds to the same set of overlapping peptides) for each respective set of overlapping peptides within the TAA. The “spotting numbers” of these 
peptides are given as well as the respective patient ID.
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of GM-CSF supports recruitment and maturation of APC, especially 
DC, and enhances cross-presentation as well as cross-priming.29–31 
Indeed, presence of T cells and APC at the sites of injection of the 
vaccine was highly increased in mice (Figure 2a and Supplementary 
Figure S2). Vaccine cells act themselves like a kind of APC especially 
due to their expression of CD80. CD80 is described to improve 
immunogenicity of co-expressed TAA, thereby supporting T-cell 
response.32 In fact, tumor-specific T cells are activated, as evident by 
increased specific cytotoxicity of spleen cells in the mouse model 
(Figure 2c) with an at least 4-week lasting effect (recovery group).
As discussed above the expression of TAA in B25MOL cells was a 
critical aspect for their selection. Many of these TAA are known to 
own immunogenic potential. Expression of TAA at protein level on 
the cell surface was roughly maintained on vaccine cells when com-
pared to B25MOL source cells (Figure 5b). This collection of endog-
enously expressed TAA is an indispensable signal for T-cell activation, 
Figure 6 Induction of antibodies against TAA by vaccination with MGN1601 in mRCC patients. Sera of all PP-treated patients (N = 10) from the ASET 
study were collected before the first vaccination and after eight vaccinations (week 12) and analyzed for binding intensity to 17 antigens (see also 
Supplementary Figures S3 and S4). Each antigen was represented by successive 15-mer peptides with an overlap of 13 amino acids. Each peptide 
was spotted in duplicate to the array. (a) Binding intensities (sera of all 10 patients) against all peptides of cyclin D1 (without any criterion for immune 
response). (b–f) Binding intensities of sera to peptides of specified TAA are depicted when three immune response criteria were fulfilled: high binding 
intensity (>1,000) of the serum combined with a greater thantwofold increase of binding signal compared to the preimmune sera and binding intensity 
in serum to overlapping peptides (with at least binding signal of 500). “ ” indicates shared immunogenic regions. (b) cyclin D1, (c) stromelysin 3, 
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whereas gene modification of B25MOL cells with the co-stimulatory 
molecules CD80 and CD154 provide their activation signals (CD154 
via activation of APC). As shown in Figure 4a,c, about 50% of vac-
cine cells express both co-stimulatory molecules. Expression of cyto-
kines is not necessarily required to happen in the same cell, as the 
cytokines are secreted. It is important to note that all four proteins 
are expressed and—in case of cytokines—secreted, despite irradia-
tion of gene-modified cells (Figure 4b). In vivo, the concentration of 
cytokines at the application site of mice increased for 8 hours and 
decreases thereafter, most probably due to degradation of cytokines, 
cytokine consumption, and their drainage from the application site 
to other body compartments like blood or lymph (Figure 4d). High 
local concentration of allogeneic tumor cells expressing their TAA 
(Supplementary Table S2) and the co-stimulatory molecules CD80 
and CD154 in the presence of the cytokines IL-7 and GM-CSF as 
well as the TLR-9 agonist dSLIM is expected to result in an immune-
responsive  microenvironment at the site of vaccination. High pres-
ence of CD4+ and CD8+ T cells as well as CD86+ APC was confirmed 
by immunohistochemistry of the injection sites.
CD4-based humoral immune response was assessed in vaccinated 
patients for a variety of TAA (about a dozen thereof are described by 
Cheever et al.33) using peptide arrays. Most strikingly, overlapping 
peptides were identified that had induced an immune response 
shared by up to 7 (out of 10) patients (Table 1), indicating a shared 
immune response to comprehensive immunogenic regions within 
some TAA. Among these is G1/S-specific cyclin-D1, a regulator of 
cyclin-dependent kinase which is overexpressed in many types of 
cancer and used as experimental target for tumor therapies.34 In the 
ASET study, 5 out of 10 patients developed antibodies reactive to 
the same or adjacent peptides within cyclin D1 (“shared immuno-
genic region”). These data are consistent with others that identified 
several peptides from cyclin D1 as T-cell epitopes.35 Another prom-
ising molecule for immunotherapeutic approach is survivin,36 an 
inhibitor of apoptosis. Currently there are several trials going on with 
survivin vaccines.37 In the ASET study, 7 out of 10 of PP-vaccinated 
patients developed antibodies against a dedicated region within 
survivin confirming the therapeutic potential of this molecule. 
Another TAA expressed in B25MOL cells is Met (Supplementary 
Table S2 and Figure  3b), the receptor for hepatocyte growth fac-
tor receptor. High protein expression of Met correlates with poor 
prognosis in RCC, and about 66% of RCC tumor material is positive 
for Met.38 The mRNA of MET is upregulated in clear cell RCC com-
pared to normal kidney39 which was confirmed for B25MOL cells. 
Vaccination of patients with MGN1601 resulted in the elicitation of a 
shared immune response to Met of three patients to comprehensive 
immunogenic regions. However, individual  Met-specific antibodies 
to overlapping peptides were detected in 7 out of 10 tested ASET 
patients (Table 1). These results are in line with other attempts using 
Met and its downstream signaling pathway as target for treatment 
of RCC.40 Furthermore, the human epidermal growth factor recep-
tor 2, Her-2/neu, is an important target in mammary carcinoma41,42 
and the focus of numerous active immunotherapy approaches.43 
More than 30% of RCC tumors express  Her-2/neu,44 and Her-2/neu 
is expressed at medium intensity on B25MOL cell surface, whereas 
ERBB2-mRNA is highly expressed. Vaccination of patients with 
MGN1601 induced antibodies that recognized peptides of Her-2/
neu in 7 out of 10 analyzed sera (individual immune response), while 
comprehensive immunogenic regions were not detected. A further 
well-known candidate for immunotherapy is MUC1 (CD227).45,46 It is 
expressed on RCC tumor material as well as on B25MOL cells (with 
medium intensity). A moderate discrepancy between mRNA data 
and fluorescence-activated cell sorting data in the vaccine cells may 
be explained by intracellular localization or shedding of MUC1. Five 
out of 10 patients developed individual MUC1-specific antibodies 
after vaccination with MGN1601 although not to comprehensive 
immunogenic regions. Other cancer-related antigens with known 
immunogenic potential like CD326 (EpCAM),47 CD146 (MCAM or 
MUC18),48 CD44, CD105 (endoglin), and CD15149 are expressed at 
mRNA and protein levels in reasonable or high amounts in B25MOL 
cells. The evaluation of immune response to those TAA remains to 
further studies. The observed increase in antibody titer after vac-
cination with MGN1601 is most probably due to either enhanced 
B-cell activation or activation of memory B cells by the vaccine. The 
finding of a shared immune response to the same peptides high-
lights the immunogenicity of the respective peptides. Nevertheless, 
it cannot be excluded that changes in the tumor mass or natural 
fluctuations may influence the titer of antibodies and contribute to 
this effect. Number of evaluated sera is too low to allow correlation 
of antibody titer with survival. This will be the aim of further studies.
According to the antibody response in patients, vaccination of 
mice with the murine homologue generated high titers of anti-
bodies responsive to lysate of Renca cells (Figure  2b). CD4-based 
humoral immune response is supported by the combined actions 
of CD154 and GM-CSF and in keeping with the ability of dSLIM to 
activate natural killer cells and B cells,7 thus probably increasing the 
antitumor effect via antibody-dependent cellular cytotoxicity.
MGN1601 was further designed to support cross-presentation 
and cross-priming, a process described to be essential for suc-
cess of tumor vaccines especially in a non–HLA-matched setting. 
 Cross-presentation means the presentation of foreign antigens on 
HLA class I molecules by APC, especially DC, whereas cross-priming 
is the downstream activation of CD8+ T cells to foreign antigens 
in lymph nodes. Besides the implication of GM-CSF31 and CD154, 
 cross-priming is further supported by the use of irradiated vac-
cine cells. Irradiation induces apoptosis, and apoptotic cells own 
an increased potential for cross-presentation.50 Finally, TLR-9 ago-
nists are shown to enhance cross-priming.27,51 Combined effects of 
these aspects should result in efficient cross-priming by MGN1601. 
Whereas combination of a cell-based vaccination strategy with 
CpG-ODN as TLR-9 agonists had been shown to increase efficacy of 
prophylactic vaccination regimens, their efficacy in therapeutic vac-
cination studies remains a matter of controversy.19,52–54
Recently, clinical guidelines for immune-related response cri-
teria were developed especially for immunotherapeutic studies 
of cancer due to the delayed response of immunologic treatment 
approaches.55,56 In fact, a delayed response to the vaccine was 
observed in mice, illustrated by the kinetic of tumor growth sup-
pression (Figure  1d). Additionally, patients with mRCC showed a 
significant benefit in overall survival only when receiving MGN1601 
therapy over 12 weeks (eight applications) indicating that the 
improved cellular and humoral immune function during MGN1601 
treatment requires time to be translated into clinical responses.
MGN1601 is the first tumor vaccine applied to humans using 
fourfold gene-modified vaccine cells in combination with a TLR-9 
agonist and owns high potential to treat RCC. This vaccine may also 
be adapted for therapies of different tumor entities.
MATeRIAlS AND MeTHODS
Manufacturing of MGN1601
B25MOL cells were harvested and transiently gene modified with MIDGE 
vectors, encoding the human forms of CD80, CD154, IL-7, and GM-CSF via 
electroporation. Gene-modified cells were combined to a homogenous 
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batch of about 2 × 109 cells, gamma irradiated with 100 Gy, and stored in 
aliquots in the vaporous phase of liquid nitrogen. Gene-modified and irradi-
ated cells after thawing and washing are called “vaccine cells.” One dose of 
MGN1601 comprised 1 × 107 vaccine cells (in a syringe) supplemented with 
5 mg dSLIM and was applied to patients within 24 hours after final prepa-
ration. Quality control data show a cell number of 0.9 × 107 ± 0.7 × 106 and 
a viability of 94.5% (± 1.5) (N  >  100). Expression of CD80 and CD154 was 
analyzed by flow cytometry, whereas expression of cytokines was quantified 
by specific enzyme-linked immunosorbent assay in the cell culture superna-
tant. For more details, see Supplementary Materials and Methods.
Animal studies
For cytokine quantification at the injection site, NMRI mice were s.c. vacci-
nated (1 × 107 vaccine cells + 5 mg dSLIM) once at two different sides with 
the murine homologue and sacrificed after the indicated time points.
Antibody production and accumulation of immune cells at the injection 
site were evaluated by vaccinating NMRI mice (2 × 106 vaccine cells + 1 mg 
dSLIM) eight times with the murine homologue of MGN1601 at four 
sites once a week. Antibody titers were analyzed from blood samples. 
Accumulation of immune cells at the injection site was ranked on frozen tis-
sue sections stained for T cells and APC by immunohistochemistry. For more 
details, see Supplementary Materials and Methods.
For determination of Renca-specific cytotoxic activity of spleen cells and 
assessment of subchronic toxicity, NMR mice received one dose of vaccine (low 
dose: 2 × 106 vaccine cells + 1 mg dSLIM; high dose: 1 × 107 vaccine cells + 5 mg 
dSLIM) or PBS as vehicle at four sites once a week for 13 consecutive weeks (six 
mice per sex and group). One week (5 weeks for recovery group) after the last 
application, mice were sacrificed, spleen cells were isolated, and co-cultured for 
12 hours with Renca cells in the presence of IL-2 (Gibco/Invitrogen, Karlsruhe, 
Germany, PMC0023). Thereafter,  re-stimulated spleen cells were mixed with 
fresh Renca cells that were analyzed 6 hours later for viability. For more details, 
see Supplementary Materials and Methods.
Balb/c received once weekly a dose of the murine vaccine (2 × 106 vaccine 
cells  +  50 µg dSLIM) for prophylactic vaccination. After four applications, 
tumor was inoculated by application of 5 × 105 native Renca cells. For more 
details, see Supplementary Materials and Methods.
Therapeutic vaccination of Balb/c mice was performed using tumor inoc-
ulation with Renca cells before treatment with the murine vaccine started 
with one dose per treatment and week for 4 weeks. Experimental variants 
of the vaccine were “Tf Renca” (gene-modified Renca cells without dSLIM), 
“Renca” (irradiated Renca cells without dSLIM), and “dSLIM” (dSLIM as single 
component). PBS was used as control. For more details, see Supplementary 
Materials and Methods.
Single- and repeated-dose (five times) testing of MGN1601 in rats (heter-
ologous setting) was performed by application of up to 1.15 × 107 vaccine 
cells (+ 1,150 µg dSLIM) by the subcutaneous route (single dose) or up to 
2.3 × 106 vaccine cells (+ 230 µg dSLIM) per application every 5 days by intra-
dermal route.
Analysis of immune response to TAA by peptide array
A phase 1/2 clinical ASET trial (ClinicalTrials.gov: NCT01265368; EudraCT 
No.: 2009-016853-16) was performed24 in accordance with the declaration 
of Helsinki, and the international conference on harmonization Guideline 
for Good Clinical Practice. All patients gave written, informed consent prior 
to participation. MGN1601 was administered intradermally eight times over 
12 weeks. Sera of patients treated per protocol were analyzed by peptide 
array. Seventeen TAA were selected (UniProt Entry number are given in 
brackets): MET (P08581), apolipoprotein L1 (O14791), G1/S-specific cyclin-
D1 (P24385), telomerase (O14746), MUC1 (P15941), survivin (Q5RAH9), Myc 
(P01106), p53 (Q2XN98), histone H1.2 (P16403), NY-ESO-1 (P78358), Her-2/
neu (P04626), MMP11 (P24347), WT-1 (P19544), G2/mitotic-specific cyclin 
B1 (P14635), PRAME (P78395), MAGE A3 (P43357), and MAGE A1 (P43355). 
Sequences were transformed into 15-mer peptides with a peptide–peptide 
overlap of 13 amino acids resulting in 4,399 different peptides that were 
spotted in duplicate onto the array. As control, the peptide microarrays were 
further framed by Flag and Hemagglutinin peptides on top and bottom 
(N = 68, each Flag and HA). Corresponding binding intensities of preimmune 
sera gained before the first application of MGN1601 and sera gained after 
the eighth application (week 12) of MGN1601 during the ASET study were 
analyzed for all 10 PP-treated patients. Signal intensities are given in arbitrary 
units. For identification of an (individual) immune response to a respective 
peptide, three aspects have to be met: signal intensity of sera > 1,000 and 
ratio (sera/preimmune sera) >2 plus at least one adjacent peptide showing 
binding intensity of >500. For identification of a shared immune response, 
sera of at least two patients have to meet the above-mentioned criteria 
for the same or adjacent peptides. For more details, see Supplementary 
Materials and Methods.
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